Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine Added to Tocilizumab for Severe COVID-19 Pneumonia
NCT05118737Phase 1Unknown
- Sponsor
- Hamad Medical Corporation
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of colchicine in COVID-19 pneumonia, sponsored by Hamad Medical Corporation. Primary endpoint: Rate of invasive mechanical ventilation at 6 months. Status: unknown.
02
Drugs
colchicine
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05118737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118737.